Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Enhancing the quality and reproducibility of research: How to work effectively with medical and data librarians
Throgmorton, Kaitlin , Festa, Natalia , Doering, Michelle , Carpenter, Christopher R. , Gill, Thomas M. , Throgmorton, Kaitlin Fender , Gill, Thomas M , Carpenter, Christopher R

Mayo Clinic

Journal of the American Geriatrics Society | January 13, 2024 | Volume: 72 | Issue: 3 | Pages: 965-970

10.1111/jgs.18741 | PMID 38217346 Get It

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer
Stinchcombe, Thomas E. , Wang, Xiaofei , Damman, Bryce , Mentlick, Jennifer, Landreneau, Rodney J., Wigle, Dennis A. , Conti, Massimo , Ashrafi, Ahmad S., Liberman, Moïshe , Mitchell, John D. , Keenan, Robert J. , Wigle, Dennis, Jones, David R , Conti, Massimo , de Perrot, Marc , Mitchell, John D , Jones, David R. , BAUER, THOMAS L , Miller, Daniel , Altorki, Nasser Khaled , Damman, Bryce

Mayo Clinic

Journal of Clinical Oncology | January 12, 2024 | Volume: 42 | Issue: 10 | Pages: 1110-1113

10.1200/jco.23.01306 | PMID 38215351 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Patients with early-stage non–small-cell lung cancer (NSCLC) who undergo curative surgical resection are at risk for developing second primary lung cancer (SPLC). Cancer and Leukemia Group B 140503 (Alliance) was a multicenter, international, randomized, phase III trial in patients with stage T1aN0 NSCLC (using the TNM staging system seventh edition) and demonstrated the noninferiority for disease-free survival between sublobar resection (SLR) and lobar resection (LR). After surgery, patients underwent computed tomography surveillance as defined by the protocol. The determination of a SPLC was done by the treating physician and recorded in the study database. We performed an analysis of the rate of SPLC (per patient per year) and the 5-year cumulative incidence in the study population and within the SLR and LR arms. Median follow-up was 7 years. The rate per patient per year in the study population, in the SLR arm, and in the LR arm was 3.4% (95% CI, 2.9 to 4.1), 3.8% (95% CI, 2.9 to 4.9), and 3.1% (95% CI, 2.4 to 4.1), respectively. The estimated 5-year cumulative incidence of SPLC in the study population, SLR arm, and LR arm was 15.9% (95% CI, 12.9 to 18.9), 17.2% (95% CI, 12.7 to 21.5), and 14.7% (95% CI, 10.6 to 18.7), respectively.
The Delphi Delirium Management Algorithms. A practical tool for clinicians, the result of a modified Delphi expert consensus approach.
Ottens, Thomas H. , Hermes, Carsten , Page, Valérie , Oldham, Mark , Arora, Rakesh C. , Bienvenu, O. Joseph , Boogaard, Mark van den , Caplan, Gideon A. , Hansen, Hans-Christian , Inouye, Sharon K. , Kamholz, Barbara, Maas, Matthew B. , MacLullich, Alasdair M. J. , Negro, Alessandra , Neufeld, Karin J. , Nydahl, Peter , Radtke, Finn M. , Raedt, Sylvie De , Rosenthal, Lisa , Vardy, Emma , Slooter, Arjen J. C. , Arora, Rakesh , van den Boogaard, Mark , Caplan, Gideon , Friedrich, Michaela-Elena , Hanison, James , Hansen, Hans-Christian , Inouye, Sharon K , Kotfis, Katarzyna , MacLullich, Alasdair M J , Marcantonio, Edward R , van Munster, Barbara C , Müller-Werdan, Ursula , Nydahl, Peter , Oh, Esther S , Pandharipande, Pratik , Radtke, Finn M , Raedt, Sylvie De , Spies, Claudia D , Vardy, Emma R L C , Wijdicks, Eelco Fm , Slooter, Arjen J C , Devlin, John W. , Kotfis, Katarzyna , Marcantonio, Edward R. , Morandi, Alessandro , Rosenthal, Lisa J., Sanders, Robert D. , Spies, Claudia , Wijdicks, Eelco F. M.

Mayo Clinic

Delirium | January 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.56392/001c.90652 | PMID 38348284 Get It

Delirium is common in hospitalised patients, and there is currently no specific treatment. Identifying and treating underlying somatic causes of delirium is the first priority once delirium is diagnosed. Several international guidelines provide clinicians with an evidence-based approach to screening, diagnosis and symptomatic treatment. However, current guidelines do not offer a structured approach to identification of underlying causes. A panel of 37 internationally recognised delirium experts from diverse medical backgrounds worked together in a modified Delphi approach via an online platform. Consensus was reached after five voting rounds. The final product of this project is a set of three delirium management algorithms (the Delirium Delphi Algorithms), one for ward patients, one for patients after cardiac surgery and one for patients in the intensive care unit.
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
Burlile, Jessica F. , Frechette, K.M., Breen, William G. , Hwang, Steven R. , Nedved, Adrienne, Harmsen, William S. , Pulsipher, Sydney , Witzig, Thomas E. , Micallef, Ivana N. , Thanarajasingam, Gita , Johnston, Patrick B. , Inwards, David J. , Peterson, Jennifer , Stish, Bradley J. , Rule, William G., Ansell, Stephen M. , Witzig, T.E. , Frechette, Kelsey M, Higgins, Alexandra S, Nedved, Adrienne N, Pulsipher, Sydney D , Hoppe, Bradford S , Bennani, N Nora , Peterson, Jennifer L , Lester, Scott C. , Burlile, Jessica , Hwang, Steven R , Higgins, Alexandra , Hoppe, Bradford S. , Habermann, Thomas M. , Bennani, N. Nora

Mayo Clinic

Blood Advances | January 11, 2024 | Volume: 8 | Issue: 5 | Pages: 1250-1257

10.1182/bloodadvances.2023011533 | PMID 38206755 Get It

Abstract Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described and are essential to defining the role of local therapies in combination with ICIs. We identified patients who received ICIs for HL between 2013 and 2022. Fludeoxyglucose-18 positron emission tomography (FDG-PET) before initiating ICI and at progression on/after ICI were reviewed, and areas of active HL were recorded. An exploratory analysis of treatable progression included patients with ≤5 sites of disease on pre-ICI FDG-PET and progression only at pre-ICI sites. Ninety patients were identified; 69 had complete records, and of these, 32 (52%) had relapsed at ICI initiation, 17 (25%) were refractory, and 16 (23%) received ICI as first-line therapy. Forty-five of 69 patients had ≤5 sites of disease (limited) on pre-ICI FDG-PET. Patients with &gt;5 sites of disease had a higher risk of progression, and every site of disease &gt;5 sites conferred an additional 1.2x higher chance of progression. At a median follow-up of 4.0 years, 41 of 69 patients had progressed on/after ICIs (cumulative incidence 66.4%), and of these, 22 of 41 patients progressed only at pre-ICI sites (cumulative incidence 39.4%). In an exploratory analysis, the cumulative incidence of a treatable progression among 45 patients with limited disease was 34%. The cumulative incidence of any progression among this cohort was 58.9%. More than one-third of patients with limited disease before ICIs experienced progression only at pre-ICI sites of disease. These patients could be candidates for radiation during or after ICIs.
Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis
Shah, Ayesha , Jones, Michael P., Callaghan, Gavin , Fairlie, Thomas, Ma, Xiaomin, Stuart, Katherine , Cruz, Peter De , O’Beirne, James , Holtmann, Gerald , Jones, Michael , Holtmann, Gerald J , Jones, Michael P , Jones, Michael P., Culver, Emma , Tabibian, James H. , Dignass, Axel , Canbay, Ali , Gores, Gregory J.

Mayo Clinic

Hepatology Communications | January 11, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000347 | PMID 38206197 Get It

Background: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment. Several studies have evaluated the effect of different biologic therapies on PSC with inconclusive findings. We conducted a systematic review and meta-analysis to assess the effects of biologics in PSC and associated inflammatory bowel disease (IBD). Methods: MEDLINE, Scopus, and Embase were searched up to July 31, 2023, for studies reporting the effects of biologics in patients with PSC-IBD. Effects of biologic therapy on alkaline phosphatase, total bilirubin, ulcerative colitis response score, and adverse events were calculated and expressed as standardized difference of means (SMD), proportions, and 95% CI using a random-effects model. Results: Six studies, including 411 PSC-IBD patients who received biologics, were included. Biologic treatment was associated with no change in alkaline phosphatase (SMD: 0.1, 95% CI: −0.07 −0.17, p=0.43), but a small and statistically significant increase in total bilirubin (SMD: 0.2, 95% CI: 0.05–0.35, p<0.01). 31.2% (95% CI: 23.8–39.7) of patients with IBD achieved endoscopic response, and there was a significant improvement in ulcerative colitis response score (SMD: −0.6,95% CI: −0.88 to 0.36, p<0.01). Furthermore, 17.6% (95% CI: 13.0–23.5) of patients experienced adverse events severe enough to discontinue therapy, and 29.9% (95% CI: 25.2–34.8) had a loss of response to biologics. Conclusions: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.
Development of a flipped learning course to deliver and scale molecular variant evaluation education: A quality improvement initiative
Balcom, Jessica R. , Ellingson, Marissa S. , Bowler, Carrie , Richardson, Darcy M., Kruisselbrink, Teresa , Thomas, Brittany C. , Bowler, Carrie A

Mayo Clinic

Journal of Genetic Counseling | January 10, 2024 | Volume: 33 | Issue: 1 | Pages: 168-178

10.1002/jgc4.1855 | PMID 38197720 Get It

AbstractOver the past several decades, molecular genetic testing volumes have grown and testing has expanded from single‐gene assays to multigene panels, exome sequencing, and genome sequencing. The number of molecular genetic variants that require manual interpretation has grown simultaneously, resulting in an increased demand for education on molecular variant evaluation (MVE). To meet this growing need, a team of genetic counselors and educational experts undertook a quality improvement (QI) initiative with the objectives of assessing, standardizing, and scaling access to MVE education, without increasing instructor time to deliver the education. Using the Six Sigma define–measure–analyze–improve–control (DMAIC) framework, a flipped learning course with a series of standardized online modules was developed to deliver MVE education in an enduring and accessible format for a diverse group of learners. Outcome measures included the number of online modules developed, the number of individual learners and unique learner groups accessing MVE education, and direct instruction time required to deliver MVE education. Countermeasures to ensure maintenance of educational quality included post‐course learner satisfaction scores and performance on competency assessments. Both the total number of learners and the number of unique learner groups accessing MVE education increased, while instructor time required to deliver content per learner decreased. Learner satisfaction scores remained constant and performance on competency assessments improved. The QI initiative successfully scaled MVE education to a diverse group of learners without decreasing learner outcomes or satisfaction. The flipped learning format provides a scalable and flexible educational model for instructors and learners in a rapidly changing environment that often includes remote work and education.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma
Kahl, Brad S. , Jegede, Opeyemi A. , Peterson, Christopher G., Swinnen, Lode J., Weiss, Matthias , Fishkin, Paul A. S., Fenske, Timothy S. , Williams, Michael E. , Weiss, Matthias , Fenske, Timothy S , Williams, Michael E , Jagede, Opeyemi A. , Kahl, Brad S , Peterson, Christopher, Habermann, Thomas M. , Schuster, Stephen J.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 7 | Pages: 774-778

10.1200/jco.23.01912 | PMID 38194625 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low–tumor burden follicular lymphoma. Rituximab-responsive patients (n = 299) were randomly assigned to either a retreatment rituximab (RR) strategy or a maintenance rituximab (MR) strategy. Each dosing strategy was continued until treatment failure. The primary end point of the study was time to treatment failure (TTF). In the original report, there was no difference in TTF between the two dosing strategies. Here, we report on the long-term outcomes for secondary end points of time to first cytotoxic therapy, duration of response, and overall survival (OS). At 7 years, 83% of MR patients had not required first chemotherapy compared with 63% of RR patients (hazard ratio, 2.37 [95% CI, 1.5 to 3.76]). At 7 years, 71% of MR remained in their first remission compared with 37% of RR patients. Despite the improved first remission length with MR, there was no difference in OS at 10 years (83% v 84%). With mature long-term data, we confirm that prolonged maintenance rituximab does not confer an OS advantage in low–tumor burden follicular lymphoma.
AMCP Market Insights Health Plan Best Practice: Implementing continuous glucose monitoring to improve patient outcomes in diabetes
Pangrace, Michael , Dolan, Sheri, Grace, Thomas , Greene, Estay, Long, Eric C., McClelland, Scott, Moore, Josh, Morgan, Diane E., Mullins, Heather, Wescott, Susan, Long, Eric, McClelland, Scott

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | January 8, 2024 | Volume: 30 | Issue: 1-a Suppl | Pages: S1-S15

10.18553/jmcp.2024.30.1-a.s1 | PMID 38190244 Get It

The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma
Laoruangroj, Chonlada , Atherton, Pamela J. , Wiseman, Gregory A., Ansell, Stephen M. , Schumacher, Peyton, Witzig, Thomas E. , Witzig, T.E. , Feldman, Andrew L.

Mayo Clinic

Leukemia & Lymphoma | January 8, 2024 | Volume: 65 | Issue: 3 | Pages: 333-338

10.1080/10428194.2023.2295792 | PMID 38189774 Get It